Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -29.57
- Piotroski Score 4.00
- Grade Buy
- Symbol (ADXN)
- Company Addex Therapeutics Ltd
- Price $7.23
- Changes Percentage (-10.86%)
- Change -$0.88
- Day Low $7.02
- Day High $8.98
- Year High $27.90
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/22/2024
- Fiscal Year End N/A
- Average Stock Price Target $30.00
- High Stock Price Target $30.00
- Low Stock Price Target $30.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$18.87
- Trailing P/E Ratio -0.48
- Forward P/E Ratio -0.48
- P/E Growth -0.48
- Net Income $-10,556,227
Income Statement
Quarterly
Annual
Latest News of ADXN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...
Non-current liabilities decreased by CHF 5.5 million to CHF 0.1 million from December 31, 2023. Details on a chronic cough program, dose terminology, competitor molecules, and future developments in n...
By Yahoo! Finance | 1 month ago
